Investor Relations

Recent News
Sep 14, 2020

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of...

Aug 6, 2020

- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC, Aug. 6, 2020 /CNW/ - Sierra Oncology, Inc....

Aug 6, 2020

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1...

View all news releases

Events and Webcasts
Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts